Arman Tabatbai writing for TechCrunch covers a fascinating topic on the future kings of American biotech finance—will it be China? Tabatbai reports that firstly it has been a record year for health and medical investments in the United States. Apparently, Chinese investors seek to lead even more deal financings in a pursuit to lead this critical industry.
TechCrunch reports that Chinese medical startups have received record amounts of capital—with over 100 financings approaching $4 billion in investment. Chinese investors seek to own the future by moving aggressively into healthcare and life sciences. Read the rest of Mr. Tabatbai’s article for a fascinating summary of the trends and patterns emerging in medical and life science investing.
Undoubtedly, Chinese investors will increasingly sit on some of America’s hottest biotech ventures.Source: TechCrunch